Tricyclic inhibitor of matrix metalloproteinases
AssigneeWarner-Lambert Company
InventorsDonald Hupe, Linda Lea Johnson, Qi-Zhuang Ye
Life of this patent
Estimating the term…
Abstract
A tricyclic compound is described as well as pharmaceutical compositions of same, which is useful as an inhibitor of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) for the treatment of multiple sclerosis or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes.
Claims5
A method of treating multiple sclerosis comprising administering to a host suffering therefrom a therapeutically effective amount of the compound of Formula I ##STR2## or corresponding isomers thereof;
- or a pharmaceutically acceptable salt thereof in unit dosage form.
A method of treating autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes comprising administering to a host suffering therefrom a therapeutically effective amount of the compound of Formula I ##STR3## or corresponding isomers thereof;
- or a pharmaceutically acceptable salt thereof in unit dosage form.
A pharmaceutical composition comprising the compound of Formula I:
- ##STR4## in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
Dependencies are inferred from the claim text.